Blinded, randomized study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals’ measles-mumps-rubella-varicella candidate vaccine given to healthy children during the second year of life
Combined Measles, Mumps, Rubella, Varicella Vaccine
Measles; Mumps; Rubella; Varicella
Phase 3
This is a follow-up study to 103388. The results of this study 104690 are summarised with primary study 103388 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided.
September 2015